Table 1.

Patient baseline and disease characteristics

All 21/7 combined (n = 41)All CDD combined (n = 28)Total (N = 69)
Age, y
 Mean (SD)57.5 (13.68)60.8 (9.03)58.8 (12.05)
 Median (range)62.0 (25–86)60.0 (43–84)60.0 (25–86)
Sex, n (%)
 Male23 (56.1)13 (46.4)36 (52.2)
 Female18 (43.9)15 (53.6)33 (47.8)
ECOG performance status, n (%)
 015 (36.6)8 (28.6)23 (33.3)
 124 (58.5)20 (71.4)44 (63.8)
 22 (4.9)02 (2.9)
Race, n (%)
 American Indian or Alaska Native01 (3.6)1 (1.4)
 Black or African American2 (4.9)2 (7.1)4 (5.8)
 White39 (95.1)25 (89.3)64 (92.8)
Weight, kg
 Mean (SD)74.45 (17.3)77.35 (23.4)75.62 (19.9)
 Median (range)72.40 (44.7–109.3)73.85 (46.3–163.5)72.40 (44.7–163.5)
Primary tumor sites, n (%)
 NSCLC12 (29.3)12 (42.9)24 (34.8)
 Breast5 (12.2)3 (10.7)8 (11.6)
 Colon5 (12.2)3 (10.7)8 (11.6)
 Other19 (46.3)10 (35.7)29 (42.0)
Years since diagnosis
 Mean (SD)4.04 (3.8)4.07 (4.5)4.05 (4.1)
 Median (range)2.78 (0.4–17.1)2.46 (0.6–22.4)2.62 (0.4–22.4)
Prior therapy, n (%)
 Prior systemic cancer therapy only14 (34.1)10 (35.7)24 (34.8)
 Prior radiation therapy only1 (2.4)01 (1.4)
 Prior systemic therapy and radiation25 (63.4)18 (64.3)43 (63.2)
 No prior therapy reported1 (2.4)01 (1.4)

Abbreviations: 21/7 = 21 consecutive days on treatment followed by 7 days off treatment; CDD, continuous once-daily dosing; NSCLC, non-small cell lung cancer; SD, standard deviation.